Kim SM Long J Montez-Rath M Leonard M Chertow GM

Hip Fracture in patients with non-dialysis-requiring chronic kidney disease.

J Bone Miner Res. 31: 1803-1809Robertson L Black C Fluck N Gordon S Hollick R Nguyen H et al.

Hip fracture incidence and mortality in chronic kidney disease: the GLOMMS-II record linkage cohort study.

BMJ Open. 8e020312Lo LWT Yanling X Chou ACC Sen Howe T Allen JC Koh JSB

End-stage renal failure is an independent risk factor for 1-year mortality after hip fracture surgery.

Geriatr Orthop Surg Rehabil. 92151459318770561Schnuelle P Lorenz D Trede M Van Der Woude FJ

Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up.

J Am Soc Nephrol. 9: 2135-2141Russell JD Beecroft ML Ludwin D Churchill DN

The quality of life in renal transplantation–a prospective study.

Transplantation. 54: 656-660Yu T-M Lin C-L Chang S-N Sung F-C Huang S-T Kao C-H

Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study.

Mayo Clin Proc. 89: 888-895Bouquegneau A Salam S Delanaye P Eastell R Khwaja A

Bone disease after kidney transplantation.

Clin J Am Soc Nephrol. 11: 1282-1296Rajapakse CS Leonard MB Bhagat YA Sun W Magland JF Wehrli FW

Micro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantation.

Radiology. 262: 912-920Julian BA Laskow DA Dubovsky J Dubovsky EV Curtis JJ Quarles LD

Rapid loss of vertebral mineral density after renal transplantation.

N Engl J Med. 325: 544-550Naylor KL Garg AX Hodsman AB Rush DN Leslie WD

Long-term changes in bone mineral density in kidney transplant recipients.

Transplantation. 98: 1279-1285Vautour LM Melton LJ Clarke BL Achenbach SJ Oberg AL McCarthy JT

Long-term fracture risk following renal transplantation: a population-based study.

Osteoporos Int. 15: 160-167Abbott KC Oglesby RJ Hypolite IO Kirk AD Ko CW Welch PG et al.

Hospitalizations for fractures after renal transplantation in the United States.

Ann Epidemiol. 11: 450-457Nikkel LE Hollenbeak CS Fox EJ Uemura T Ghahramani N

Risk of fractures after renal transplantation in the United States.

Transplantation. 87: 1846-1851Marques IDB Araújo MJCLN Graciolli FG Dos Reis LM Pereira RMR Alvarenga JC et al.

A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation.

J Am Soc Nephrol. 30: 355-365Evenepoel P Claes K Meijers B Laurent MR Bammens B Naesens M et al.

Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol.

Nephrol Dial Transplant. 35: 697-705Nair SS Lenihan CR Montez-Rath ME Lowenberg DW Chertow GM Winkelmayer WC

Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States.

Am J Transplant. 14: 943-951Naylor KL Jamal SA Zou G McArthur E Lam NN Leslie WD et al.

Fracture incidence in adult kidney transplant recipients.

Transplantation. 100: 167-175Lee ES Lim J-H Cho J-H Jung H-Y Choi J-Y Park S-H et al.

Pretransplant osteoporosis and osteopenia are risk factors for fractures after kidney transplantation.

Transplant Proc. 51: 2704-2709Akaberi S Simonsen O Lindergård B Nyberg G

Can DXA predict fractures in renal transplant patients?.

Am J Transplant. 8: 2647-2651

Prevention and rehabilitation of osteoporosis.

Wien Med Wochenschr. 166: 22-27Wolf M Weir MR Kopyt N Mannon RB Von Visger J Deng H et al.

A prospective cohort study of mineral metabolism after kidney transplantation.

Transplantation. 100: 184-193Iyer SP Nikkel LE Nishiyama KK Dworakowski E Cremers S Zhang C et al.

Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton.

J Am Soc Nephrol. 25: 1331-1341Nikkel LE Mohan S Zhang A McMahon DJ Boutroy S Dube G et al.

Reduced fracture risk with early corticosteroid withdrawal after kidney transplant.

Am J Transplant. 12: 649-659

The bone after kidney transplantation.

Clin J Am Soc Nephrol. 14: 795-797Wolf M Molnar MZ Amaral AP Czira ME Rudas A Ujszaszi A et al.

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

J Am Soc Nephrol. 22: 956-966Schreiber PW Bischoff-Ferrari HA Boggian K Bonani M van Delden C Enriquez N et al.

Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation.

PLoS One. 13e0191167Perrin P Caillard S Javier RM Braun L Heibel F Borni-Duval C et al.

Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation.

Am J Transplant. 13: 2653-2663

New insights to fibroblast growth factor 23 in kidney transplant.

J Am Soc Nephrol. 22: 799-801Urakawa I Yamazaki Y Shimada T Iijima K Hasegawa H Okawa K et al.

Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Nature. 444: 770-774

Mineral (mal)adaptation to kidney disease–Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.

Clin J Am Soc Nephrol. 10: 1875-1885Saito H Maeda A Ohtomo S-I Hirata M Kusano K Kato S et al.

Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

J Biol Chem. 280: 2543-2549

FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Nat Rev Nephrol. 16: 7-19Ix JH Shlipak MG Wassel CL Whooley MA

Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study.

Nephrol Dial Transplant. 25: 993-997Neves CL dos Reis LM Batista DG Custodio MR Graciolli FG de Martin R et al.

Persistence of bone and mineral disorders 2 years after successful kidney transplantation.

Transplantation. 96: 290-296

Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: a prospective study.

Clin Transplant. 21: 683-688Naylor KL Zou G Leslie WD Hodsman AB Lam NN McArthur E et al.

Risk factors for fracture in adult kidney transplant recipients.

World J Transplant. 6: 370-379Ball AM Gillen DL Sherrard D Weiss NS Emerson SS Seliger SL et al.

Risk of hip fracture among dialysis and renal transplant recipients.

JAMA. 288: 3014-3018Lenihan CR Sukumaran Nair S Vangala C Ramanathan V Montez-Rath ME Winkelmayer WC

Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients.

Am J Kidney Dis. 69: 595-601Naylor KL Leslie WD Hodsman AB Rush DN Garg AX

FRAX predicts fracture risk in kidney transplant recipients.

Transplantation. 97: 940-945Perrin P Kiener C Javier R-M Braun L Cognard N Gautier-Vargas G et al.

Recent changes in chronic kidney disease-mineral and bone disorders and associated fractures after kidney transplantation.

Transplantation. 101: 1897-1905Chavassieux P Portero-Muzy N Roux J-P Garnero P Chapurlat R

Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?.

J Clin Endocrinol Metab. 100: 4662-4668Tartaglione L Pasquali M Rotondi S Muci ML Leonangeli C Farcomeni A et al.

Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation.

PLoS One. 12e0178637Coco M Pullman J Cohen HW Lee S Shapiro C Solorzano C et al.

Effect of risedronate on bone in renal transplant recipients.

J Am Soc Nephrol. 23: 1426-1437

Noninvasive imaging of bone microarchitecture in patients receiving renal transplant: can it replace histology?.

Clin J Am Soc Nephrol. 12: 562-564Hans D Goertzen AL Krieg M-A Leslie WD

Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study.

J Bone Miner Res. 26: 2762-2769Luckman M Hans D Cortez N Nishiyama KK Agarawal S Zhang C et al.

Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients.

Clin J Am Soc Nephrol. 12: 644-652Malakoutian T Mirzaei A Shiroudbakhshi A Amini Kadijani A Tehrani-Banihashemi A Zabihiyeganeh M

The added value of trabecular bone score in fracture risk assessment of kidney transplant recipients.

Iran J Kidney Dis. 14: 300-307Monier-Faugere MC Mawad H Qi Q Friedler RM Malluche HH

High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation.

J Am Soc Nephrol. 11: 1093-1099Cejka D Benesch T Krestan C Roschger P Klaushofer K Pietschmann P et al.

Effect of teriparatide on early bone loss after kidney transplantation.

Am J Transplant. 8: 1864-1870Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group

KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

Kidney Int Suppl. 7: 1-59Aroldi A Tarantino A Montagnino G Cesana B Cocucci C Ponticelli C

Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study.

Transplantation. 63: 380-386Ing SW Sinnott LT Donepudi S Davies EA Pelletier RP Lane NE

Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients.

Clin Transplant. 25: E113-E123Farmer CKT Hampson G Abbs IC Hilton RM Koffman CG Fogelman I et al.

Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density.

Am J Transplant. 6: 2929-2936McGregor R Li G Penny H Lombardi G Afzali B Goldsmith DJ

Vitamin D in renal transplantation - from biological mechanisms to clinical benefits.

Am J Transplant. 14: 1259-1270Jeffery JR Leslie WD Karpinski ME Nickerson PW Rush DN

Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.

Transplantation. 76: 1498-1502Brown AJ Finch J Slatopolsky E

Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport.

J Lab Clin Med. 139: 279-284Trillini M Cortinovis M Ruggenenti P Reyes Loaeza J Courville K Ferrer-Siles C et al.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

J Am Soc Nephrol. 26: 1205-1214Neer RM Arnaud CD Zanchetta JR Prince R Gaich GA Reginster JY et al.

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

N Engl J Med. 344: 1434-1441Evenepoel P Cooper K Holdaas H Messa P Mourad G Olgaard K et al.

A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism.

Am J Transplant. 14: 2545-2555Cruzado JM Moreno P Torregrosa J V Taco O Mast R Gómez-Vaquero C et al.

A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism.

J Am Soc Nephrol. 27: 2487-2494Kendler DL Roux C Benhamou CL Brown JP Lillestol M Siddhanti S et al.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

J Bone Miner Res. 25: 72-81Cummings SR San Martin J McClung MR Siris ES Eastell R Reid IR et al.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

N Engl J Med. 361: 756-765Iseri K Watanabe M Yoshikawa H Mitsui H Endo T Yamamoto Y et al.

Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial.

J Bone Miner Res. 34: 1014-1024Jamal SA Ljunggren O Stehman-Breen C Cummings SR McClung MR Goemaere S et al.

Effects of denosumab on fracture and bone mineral density by level of kidney function.

J Bone Miner Res. 26: 1829-1835Tsourdi E Langdahl B Cohen-Solal M Aubry-Rozier B Eriksen EF Guañabens N et al.

Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS.

Bone. 105: 11-17Bonani M Frey D Brockmann J Fehr T Mueller TF Saleh L et al.

Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial.

Am J Transplant. 16: 1882-1891Walsh SB Altmann P Pattison J Wilkie M Yaqoob MM Dudley C et al.

Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.

Am J Kidney Dis. 53: 856-865Torregrosa J-V Fuster D Gentil M-A Marcen R Guirado L Zarraga S et al.

Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.

Transplantation. 89: 1476-1481Torregrosa J-V Fuster D Monegal A Gentil MA Bravo J Guirado L et al.

Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.

Osteoporos Int. 22: 281-287Grotz W Nagel C Poeschel D Cybulla M Petersen KG Uhl M et al.

Effect of ibandronate on bone loss and renal function after kidney transplantation.

J Am Soc Nephrol. 12: 1530-1537Haas M Leko-Mohr Z Roschger P Kletzmayr J Schwarz C Mitterbauer C et al.

Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.

Kidney Int. 63: 1130-1136Cruz DN Brickel HM Wysolmerski JJ Gundberg CG Simpson CA Kliger AS et al.

Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate.

Am J Transplant. 2: 62-67Coco M Glicklich D Faugere MC Burris L Bognar I Durkin P et al.

Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate.

J Am Soc Nephrol. 14: 2669-2676Smerud KT Dolgos S Olsen IC Åsberg A Sagedal S Reisæter AV et al.

A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.

Am J Transplant. 12: 3316-3325Kovac D Lindic J Kandus A Bren AF

Prevention of bone loss with alendronate in kidney transplant recipients.

Transplantation. 70: 1542-1543Giannini S D'Angelo A Carraro G Nobile M Rigotti P Bonfante L et al.

Alendronate prevents further bone loss in renal transplant recipients.

J Bone Miner Res. 16: 2111-2117Schwarz C Mitterbauer C Heinze G Woloszczuk W Haas M Oberbauer R

Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation.

Kidney Int. 65: 304-309Naylor KL Zou G Leslie WD McArthur E Lam NN Knoll GA et al.

Frequency of bone mineral density testing in adult kidney transplant recipients from Ontario, Canada: a population-based cohort study.

Can J Kidney Health Dis. 3: 2